Citations

Clear

585 citation(s) found for "Tran, N".

AXIN1 Mutated Hepatocellular Carcinoma
Torbenson, Michael, McCabe, Chantal E. , Hohenstein, Jessica D. , O’Brien, Daniel, Chen, Zongming Eric, Wu, Tsung‐Teh, Kakar, Sanjay, Tran, Nguyen H., Wang, Chen, Torbenson, Michael , Kakar, Sanjay , Wang, Chen

Mayo Clinic

American Journal of Surgical Pathology | March 10, 2026 | Volume: 50 | Issue: 6 | Pages: 642-655

10.1097/pas.0000000000002528 | PMID 41804058 Get It

CTNNB1- mutated hepatocellular carcinomas are characterized by a distinctive morphology and activation of the Wnt pathway. AXIN1 also plays a key role in the Wnt pathway, but the morphology of AXIN1-mutated tumors has not been examined. In addition, there are ongoing questions on the ability of AXIN1 mutations to activate the Wnt pathway in hepatocellular carcinoma. AXIN1 mutated tumors (N=18) were studied, along with control groups: CTNNB1 (N=17), APC (6), or “Other” genes in the Wnt pathway (5). Wnt pathway activation was studied by immunostains for beta-catenin and glutamine synthetase. Findings were supplemented by gene expression analysis using TCGA data. On histologic examination, the classic morphology associated with beta-catenin mutations was found in all 4 groups: 8/18 AXIN1 (44%), 10/17 CTNNB1 (59%), 4/6 APC (67%), and 1/5 Other (20%). By immunohistochemistry, Wnt pathway activation was found in 11/18 AXIN1 (61%), 15/17 CTTNB1 (88%), 6/6 APC (100%), and 5/5 (100%) of Other. In AXIN1- mutated tumors, the Wnt pathway was weakly activated. Glutamine synthetase stains also highlighted a new “progressed pattern” associated with distinct subnodules of staining. Tertiary lymphoid structures were uncommon except for cases with CTTNNB1 mutations plus additional mutations in the Wnt pathway. In summary, the classic morphology associated with CTNNB1 mutations is found in hepatocellular carcinomas with mutations in AXIN1 , APC , and other Wnt genes. AXIN1 mutated tumors have Wnt activation that is detectable but at lower levels than CTNNB1 mutated tumors. As tumors progress, their level of Wnt activation can change.
Monogenic Etiologies of Kidney Cysts in the Pediatric Population
Bozkurt, Elif G. , Najeeb, Mohamad Sheikh, Yang, Hana , Kemppainen, Jennifer L., Smith, Byron H. , Gregory, Adriana , Baker, Tracy A., Thompson, W. Foster, Khalifa, Muhammed, Cruz, Conrad , Kouri, Anne M. , Tran, Cheryl L. , Sas, David J. , Cramer, Carl H. , Kline, Timothy L. , Torres, Vicente, Chebib, Fouad T., Harris, Peter, Thompson, Whitney S. , Baker, Tracy A. , Sheikh Najeeb, Mohamad, Gregory, Adriana V , Baker, Tracy A , Thompson, Whitney S , Dahl, Neera K , Kline, Timothy L , Torres, Vicente E , Chebib, Fouad T , Harris, Peter C , Hanna, Christian , Smith, Byron , Dahl, Neera K. , Chebib, Fouad T. , Harris, Peter C. , Hanna, Christian

Mayo Clinic

Clinical Journal of the American Society of Nephrology | March 6, 2026 | Volume: 21 | Issue: 6 | Pages: 984-996

10.2215/cjn.0000001027 | PMID 41790507 Get It

Key Points In a cohort of children, 79% of families with kidney cysts had a monogenic diagnosis. Resolved cases were more likely to have a family history of kidney cysts and unresolved cases more often had unilateral cysts. Broad genetic testing revealed genetic diversity and informed prognosis and clinical management in childhood kidney cysts. Background Pediatric kidney cysts may indicate an underlying genetic disorder, yet the full spectrum of causes remains incompletely defined. With advances in genetic testing enabling broader evaluation, this study assessed the diagnostic utility of comprehensive genetic testing in a broad pediatric cohort with kidney cysts and characterized the underlying etiological diversity. Methods This observational cohort study included patients younger than 18 years enrolled between January 2020 and June 2024 at a single tertiary center. Genetic testing used targeted multigene or custom curated exome/genome sequencing panels, with segregation analysis when available. Eligible participants had at least two cysts without family history, one cyst with positive family history, or enlarged echogenic kidneys on prenatal ultrasound; those with congenital anomalies of the kidney and urinary tract associated with cysts were excluded. Clinical presentation was categorized as symptomatic, incidental, prenatal, or family screening. Primary outcomes were diagnostic yield and distribution of pathogenic variants. Results Among 109 patients (median age 7.6 years, 53% female), genetic testing identified a definitive diagnosis in 81 of 100 tested patients (81%) from 72 families (79%; 14 disorders). PKD1 variants were most common (45%), while PKD2 accounted for 7%. Other causes included HNF1B or 17q12 deletions (13%), minor autosomal dominant polycystic kidney disease genes (11%; GANAB, NEK8, IFT140 ), monoallelic PKHD1 (3%), and biallelic PKHD1 (8%), while syndromic ciliopathy genes accounted for 5%. A positive family history of cystic kidney disease was more common among patients with a genetic diagnosis (54% versus 11%; P = 0.008). Patients without an identified genetic diagnosis more often had unilateral cysts (26% versus 4%; P = 0.53). Diagnosis by clinical symptoms was the most genetically diverse category. Conclusions Comprehensive genetic testing in pediatric kidney cysts achieved high diagnostic yield in a selected cohort and identified diverse causes beyond major autosomal dominant polycystic kidney disease/autosomal recessive polycystic kidney disease genes, supporting early evaluation to improve diagnostic accuracy, inform prognosis, and guide management, even in the absence of family history.
Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.
Shi, Xiaolei, Alshalalfa, Mohammed , Boytim, Ella, Karnes, R. Jeffrey, Spratt, Daniel Eidelberg, Lacuna, Kristine Peregrino , Halabi, Susan, Sharifi, Nima , Tang, Chad, Ross, Ashley, Davicioni, Elai, Antonarakis, Emmanuel S., Ryan, Charles J. , Tran, Phuoc T., Hwang, Justin, Halabi, Susan , Lacuna, Kristine P. , Halabi, Susan , Karnes, R. Jeffrey , Shetty, Amol Carl , Bergom, Hannah E. , Patel, Krishnan R. , Tang, Chad , Davicioni, Elai , Antonarakis, Emmanuel S.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 382-382

10.1200/jco.2026.44.7_suppl.382 Get It

382 Background: Androgen receptor signaling drives prostate cancer (PC) progression, and genes involved in androgen production, uptake, and conversion (APUC) are key therapeutic targets. We previously defined a 6-APUC gene set ( HSD3B1, HSD3B2, CYP3A43, CYP11A1, CYP11B1, and CYP17A1 ), that identified metastatic PC with favorable prognosis and predict docetaxel benefit. However, the expression landscape and clinical relevance of APUC genes have not been interrogated in localized PC. Methods: We analyzed the expression of 21 APUC genes in 55,329 radical prostatectomy tumor samples that underwent Decipher prostate genomic classifier (GC) testing (Veracyte Inc) between 2016-2024. Baseline clinical/pathologic factors were retrieved from Decipher GRID database (NCT02609269). Associations between gene expression quartiles with PathoGenomic Risk Factors (PGRF) including Very High Decipher score >0.85 (VHD), Grade Group (GG) 4-5, LNI and SVI were examined. Associations with distant metastatic (DM) outcomes and metastasis free survival (MFS) were evaluated using logistic regression in Mayo545 and Cox regression in Meta855 RP cohorts, respectively. Results: High expression of SRD5A2 was associated with favorable PGRF (lower odds ratio (OR), p<0.0001), lower rate of development of DM (OR 0.36, p<0.05), and longer MFS (Hazard ratio (HR) 0.51, p<0.05). HSD17B6 showed similar results for PGRF (lower OR, p<0.0001), DM (OR 0.58, p<0.05) and longer MFS (HR 0.39, p<0.05) despite being associated with GG4-5 and SVI+ in samples with VHD. In contrast, high expression of SRD5A3 and HSD17B10 had high OR for PGRFs (p<0.0001). High expression of SLCO2B1 , an androgen uptake gene, had the strongest association with GG4-5 and SVI/LNI (p<0.001 for both). We noted that SRD5A2 lacked correlation with SRD5A1 and SRD5A3 , which instead correlated with each other. Compared to all APUC genes, SRD5A2 had limited correlations with almost all APUC genes, including ones that exhibited robust cross correlation with each other . Similar to our prior finding, most APUC genes demonstrated negative correlation with AR expression and AR activity signatures. Key outcomes were validated based on transcriptomic data from 492 samples from TCGA database. Conclusions: Comprehensive analysis of 21 APUC genes in over 55,000 PC identified distinct, context-dependent associations with metastatic outcomes and clinical and molecular risk factors. Notably, high SRD5A2 expression was associated with lower odds of high-risk features and metastatic outcomes, whereas SRD5A1 and SRD5A3 linked to adverse outcomes, suggesting critical yet divergent roles among 5-alpha-reductase family members. These findings underscoring androgen-metabolic heterogeneity and highlighting SRD5A2 as a potential biomarker of indolent biology in localized prostate cancer.
A clinical, evidence-based risk estimator for individualizing benefit and response in oligometastatic prostate cancer (CEREBRO): A tool from the X-Met collaboration.
Ost, P.I.E.T., Hwang, Hyunsoo , Msaouel, Pavlos, Francolini, Giulio, Livi, L., Tran, Phuoc T., Kiess, Ana P. , Wang, Jarey, Phillips, Ryan, Deek, Matthew P. , Jereczek-Fossa, Barbara Alicja, Ludmir, Ethan B., Blanchard, P., Sun, Ryan, Palma, David A. , Tang, Chad, Sherry, Alexander D. , Msaouel, Pavlos , Francolini, Giulio , Phillips, Ryan , Marvaso, Giulia , Jereczek‐Fossa, Barbara Alicja , Ludmir, Ethan B. , Blanchard, Pierre , Sun, Ryan , Tang, Chad

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 160-160

10.1200/jco.2026.44.7_suppl.160 Get It

160 Background: To our knowledge, no tools are available to guide care in oligometastatic prostate cancer (omPC). Here, we leveraged individual patient-level data pooled from 8 randomized trials in the X-Met collaboration to construct CEREBRO, a tool for predicting patient-specific responses to various treatment scenarios. Methods: Patients with omPC from the STOMP, ORIOLE, SABR COMET, EXTEND continuous ADT, EXTEND intermittent ADT, ARTO, RADIOSA, and RAVENS trials were included. 6 patients (1%) with missing data were excluded. Treatment scenarios were defined as active surveillance (AS), metastasis-directed therapy (MDT), systemic therapy (ST), or MDT+ST. To account for varying baseline hazards, Weibull models were fit for overall survival (OS); progression-free survival (PFS); and castration-resistance free survival (CRFS) for patients with hormone-sensitive disease. Endpoint definitions were harmonized per X-Met framework. Results: Of 600 patients included (treatment scenarios: AS=50; MDT=153; ST=172; MDT+ST=225), 405 (67%) had hormone-sensitive omPC. With median follow-up of 38 months, median PFS, CRFS, and OS of all patients were 18, 70, and 84 months. In order of relative contribution, inputs for predicting outcomes were: treatment scenario, stage, prostate-specific antigen annotated by ADT status, metachronous vs synchronous presentation, imaging type, number of metastases, hormone sensitivity, and age. The model for each endpoint showed robust fit, calibration, superiority against the null model (per the likelihood ratio test), and risk stratification (Table). Median PFS times for model-defined low-, intermediate-, and high-risk strata were 46 months, 18 months, and 7 months ( p <0.0001). In addition, the PFS and OS models also showed strong discrimination via c index and a large interval of risk probabilities with additive clinical utility per decision-curve analysis (Table). A public webpage will be made available to facilitate prospective trial stratification, patient counseling for patient-specific outcome predictions for each potential treatment scenario, and forecasts comparing outcomes between treatment scenarios. Conclusions: CEREBRO is a high-performance tool, trained on robust prospective data from 8 randomized trials with routinely collected clinical variables, for predicting risk and treatment outcomes in omPC. Given the uncertainties in optimal timing of MDT and combination with ST, this tool has been built to facilitate current decision making. External validation is planned. Model summary. Endpoint C index (95% CI) Calibration Likelihood ratio p Risk strata p Net clinical utility observed between thresholds PFS 0.72 (0.70-0.75) 1.04 <0.0001 <0.0001 0.2-1.0 CRFS 0.63 (0.60-0.70) 1.01 0.02 0.004 0.2-0.5 OS 0.81 (0.76-0.86) 1.01 <0.0001 <0.0001 0.05-1.0
Utilization of bone modifying agents in metastatic hormone resistant prostate cancer: A retrospective study of real world patients.
Chohan, Yashveer, Ganadily, Naif A., Barker, Kenneth, Oberoi, Japneet Kaur , Afzal, M. , Tran, Phu N. , Orme, Jacob J. , Basu, Arnab, Kase, Adam M. , Heath, Elisabeth I. , Cobran, Ewan Kemar, Singh, Parminder, Barker, Kenneth N. , Childs, Daniel S. , Bryce, Alan H. , Cobran, Ewan K. , Singh, Parminder Pal , Zakharia, Yousef , Riaz, Irbaz Bin

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 127-127

10.1200/jco.2026.44.7_suppl.127 Get It

127 Background: Bone metastases affect up to 90 % of patients with metastatic hormone-resistant prostate cancer (mHRPC) and cause substantial morbidity from skeletal-related events (SREs) such as fracture, spinal-cord compression, and palliative interventions. Bone-modifying agents (BMAs) including bisphosphonates and denosumab reduce SRE risk and are NCCN-recommended, however, real-world use remains inconsistent. Methods: Patients with mHRPC treated from January 2017-September 2024 across Mayo Clinic sites were identified using SQL-based EHR queries confirmed by manual chart review. Bone Metastases were detected through keyword searchers of radiology reports and confirmed through manual chart review. SRE-prevention dosing was defined as zoledronic acid 4mg IV or denosumab 120mg SC; osteoporosis dosing was excluded. SREs were identified using diagnosis codes and text-pattern searches for radiotherapy, surgery, fracture, and spinal-cord compression. Descriptive statistics summarized BMA utilization and SRE incidence. Categorical variables were compared using Chi-square tests, and a risk ratio (RR) with 95% confidence intervals was calculated to evaluate association between early BMA initiation and SRE risk. Results: Among 778 patients with mHRPC, 685 (88 %) had bone metastases (mean age 70.5 years). Of these, 169 (24.7 %) had an SRE, and 261 (38.1 %) received BMAs at SRE-prevention doses (denosumab n = 157 [60 %]; zoledronic acid n = 104 [40 %]). Based on a chi-square test, combined SRE incidence did not differ significantly (No BMA 23 %, denosumab 23 %, zoledronic 33 %; p = 0.069). Bone pain at baseline was more common in patients who later received a BMA (136 [68 %]) than in those who did not (82 [41 %]; p < 0.001). Among 200 randomly sampled non-BMA patients, 83 had no recorded BMA discussion (66 also lacked bone pain), 38 lacked dental clearance, 32 had uncompleted plans and 18 declined therapy. Early BMA initiation (before first bone metastases) was associated with fewer SREs (16 % vs 29 %; RR 0.56, 95 % CI 0.33–0.96). Conclusions: Less than half of bone-metastatic mHRPC patients received BMAs. Non-initiation was often linked to modifiable factors such as delayed dental clearance or lack of treatment discussions, highlighting the need for system-level strategies to improve timely bone-directed care. SREs were common, affecting one quarter of patients. Small sample size precluded meaningful comparison of the impact of BMAs on SRE incidence however early BMA initiation may lower SREs. Incidence of SREs stratified by no BMA vs BMA treatment. SRE No BMA BMA Overall Pathological Fracture 6.4% (27/424) 4.9% (13/261) 5.8% (40/685) Radiotherapy to Bone 13.9% (59/424) 18.8% (49/261) 15.7% (108/685) Spinal Cord Compression 0.7% (3/424) 3.1% (8/261) 1.6% (11/685) Surgery to Bone 2.1% (9/424) 0.3% (1/261) 1.5% (10/685) Combined 23% (98/424) 27.2% (71/261) 24.7% (169/685)
Artificial intelligence (AI)–assisted eligibility screening for prostate cancer clinical trial matching.
Tran, Phu N. , Cingolani, Filippo , Naqvi, Syed Arsalan Ahmed , Ayub, Umair , Khoury, Peter R., Heath, Elisabeth I., Velcheti, V., Bekaii-Saab, Tanios S., Singh, Parminder Pal , Heath, Elisabeth I., Giridhar, Karthik V. , Tevaarwerk, Amyé , Bekaii-Saab, Tanios S., Zakharia, Yousef , Riaz, Irbaz Bin

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 405-405

10.1200/jco.2026.44.7_suppl.405 Get It

405 Background: Clinical trials are critical to advancing prostate cancer treatment, yet patient enrollment remains a major bottleneck. Despite strong interest in AI for trial matching, real-world use remains limited due to reasons such as complex infrastructure requirements. To address this, we developed a lightweight, scalable AI framework leveraging the Google Healthcare Search API—requiring minimal technical expertise—to automate trial eligibility screening. Methods: We used a pre-trained GPT-5 large language model (LLM) to decompose the eligibility criteria of 13 prostate cancer clinical trials into 269 YES/NO questions, such that for an eligible patient of a given trial, the chart review would yield YES for inclusion and NO for exclusion questions. From 348 patients enrolled in one of the trials, we built a dataset linking each eligibility question to each patient, resulting in 4,947 patient–question pairs (2,034 inclusion pairs with YES labels and 2,913 exclusion pairs with NO labels). The task was framed as binary classification. During evaluation, for each patient–question pair, the LLM extracted search phrases from the question to retrieve relevant EHR information via the Google Healthcare Search API, then used the question and retrieved information to predict YES or NO responses. Performance was measured using accuracy, precision, recall, specificity, and F1 score. Results: Across 4,947 question–patient pairs, our framework achieved 0.81 accuracy, 0.85 precision, 0.65 recall, 0.92 specificity and a F1 score of 0.74. Results for different phases of trials is reported in Table 1, which demonstrates the approach’s robustness across trial phases. Predictions for exclusion criteria were highly precise, while inclusion criteria were more challenging. Most errors were observed in criteria involving complex nested logical conditions, interpretable clinical definitions and data not explicitly measurable or recorded in the EHR (e.g., planned treatments or clinician-assessed scores). Conclusions: This work demonstrates a practical AI framework to support clinical trial matching. The system can identify complex disease states (biochemical recurrence vs radiographic metastasis), castration status (sensitive, resistant) and genomics. Future work should focus on developing human-in-the-loop supervision and improving question decomposition to reduce errors in complex eligibility criteria. Screening performance of the proposed framework across different phases of trials. Trial Phase #Patient-Question Pairs #YES/NO labels Accuracy Precision Recall Specificity F1 score I, II, I/II 4,227 Yes: 1,735 No: 2,492 0.80 0.84 0.66 0.92 0.74 III 720 Yes: 299 No: 421 0.82 0.90 0.63 0.95 0.74 All 4,947 Yes: 2,034 No: 2,913 0.81 0.85 0.65 0.92 0.74 #YES/NO labels: The number of patient-question pairs that are labeled YES/NO among total patient-question pairs of the same row.
Abstract PS3-08-13: Exploratory analysis of palbociclib benefit in the PALLAS trial by SETERPR index and prior chemotherapy regimens (ABCSG-42/AFT-05/BIG-14-13)
Metzger, Otto, O'Brien, P., Ballman, K. V., Gnant, M., Watson, M. A., Chen, Eveline , Tran, Kevin, Martín, M., Balko, J., Nowecki, Z. I., Hahn, O. M., Denkert, C., Curtis, C., Liu, F., Dueck, A., Fesl, Christian , Mayer, E. L., Michele, A. De, Symmans, W. F., O'Brien, P., Ballman, K. V., Gnant, Michael , Hlauschek, Dominik , Balko, J. M., Curtis, Christina , Symmans, W. Fraser

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-08-13-PS3-08-13

10.1158/1557-3265.sabcs25-ps3-08-13 Get It

Abstract Background PALLAS trial compared palbociclib plus endocrine therapy (ET) vs. ET alone in stage II-III HR+/HER2- breast cancer. SETER/PR index quantifies transcriptional activity related to estrogen and progesterone receptors and serves as a measure of endocrine sensitivity. In CALGB 9741, low SETER/PR (&lt; 0.75) - reflecting endocrine resistance - predicted survival benefit from adjuvant anthracycline/taxane-based treatment. In PALLAS low SETER/PR was associated with worse prognosis and early recurrence. Early recurrences driven by endocrine-resistant tumors may obscure the benefit of palbociclib by disproportionately contributing events from a more resistant population. We hypothesized that palbociclib efficacy might vary by endocrine sensitivity and prior chemotherapy regimen, with greatest benefit in patients with intermediate SETER/PR index. Methods Invasive disease-free survival (iDFS) was summarized with Kaplan-Meier plots and the treatment arms were compared with a log-rank test. Cox models estimated the hazard ratio (HR) with 95% confidence interval (95%CI) (significance level used was a two-sided 0.05). SETER/PR index was successfully obtained for 3,090 PALLAS patients (TransPALLAS ITT cohort, Metzger et al. ASCO 2024). SETER/PR index cut points (0.75 and 1.50) were proposed from previous studies comparing different adjuvant chemotherapy regimens. Results Table 1 summarizes the efficacy of adjuvant palbociclib by prior (neo)adjuvant chemotherapy regimen. Palbociclib was associated with longer iDFS in the group who received prior anthracycline-paclitaxel chemotherapy (AC-P), though the chemo regimen x palbociclib interaction term was not significant (Table 1). In the 1,132 patients from the TransPALLAS cohort who received AC-P chemotherapy, the 518 (46%) patients with intermediate SETER/PR (0.75≤ SETER/PR &lt;1.50) had longer iDFS with palbociclib (HR 0.58; 95% CI: 0.40-0.84; p=0.004; 7-yr iDFS 80.2% vs. 68.4%), but this subset did not predict palbociclib benefit relative to all others, i.e., 206 (18%) patients with low SETER/PR (&lt;0.75) and 408 (36%) high SETER/PR (≥1.50); P interaction=0.11. Exploratory analysis of SETER/PR index as a continuous variable in patients who received prior AC-P chemotherapy revealed a non-linear relationship with the hazard ratio favoring palbociclib observed in the subset with SETER/PR values between 1.1 and 1.8, compared to all others (P interaction=0.01). Conclusions In PALLAS, we observed a numerical benefit favoring palbociclib among pts treated with adjuvant AC-P; in this subset a moderate level of endocrine transcriptional activity (SETER/PR index between 1.1 and 1.8) predicted palbociclib benefit. These results are hypothesis-generating. Citation Format: O. Metzger, P. O'Brien, K. Ballman, M. Gnant, M. Watson, E. Chen, K. Tran, D. Hlauschek, M. Martin, J. Balko, Z. Nowecki, O. Hahn, C. Denkert, C. Curtis, F. Liu, A. Dueck, C. Fesl, E. Mayer, A. De Michele, W. Symmans. Exploratory analysis of palbociclib benefit in the PALLAS trial by SETERPR index and prior chemotherapy regimens (ABCSG-42/AFT-05/BIG-14-13) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-08-13.
Clinical Features and Dental Pathologies in Maxillary Sinus Fungal Balls and Odontogenic Sinusitis
Im, E., Donaldson, Lane , Adappa, Nithin D, Chen, Y. P., Chapurin, Nikita , Espinosa, Maria, Fu, Chia‐Hsiang , Fox, Meha G, Garg, Rohit, Kohanski, Michael A. , Li, Kevin L. , Liu, Duxuan , Locke, Tran Bao, Lin, Chih‐Feng, Ottavi, Alice, Papagiannopoulos, Peter , Je, Palmer, Tong, C., Tajudeen, Bobby A. , Venkatesh, Sanjena , Wei, Kimberly , Yoo, Frederick , Yu, Alison J. , Jin, Jun, Saibene, Alberto Maria , Craig, John, Im, Eunice , Douglas, Jennifer E , Eide, Jacob, Espinosa, Maria , Fox, Meha G , Locke, Tran Bao , Makary, Chadi , Venkatesh, Sanjena , Saibene, Alberto M , Adelman, Avraham E. , Adappa, Nithin D. , D’Souza, Glen , Eide, Jacob G. , Fox, Meha G. , Garg, Rohit , Kuan, Edward C , Kwiatkowska, Marta Aleksandra , Liu, Derek H., Locke, Tran B. , Jin, Jun

Mayo Clinic

The Laryngoscope | February 8, 2026 | Volume: 136 | Issue: 7 | Pages: 2913-2924

10.1002/lary.70429 | PMID 41654324 Get It

ABSTRACT Objectives While maxillary sinus fungal balls (MSFB) can be associated with odontogenic conditions (MSFBO), MSFBO clinical and dental features have not been compared to odontogenic sinusitis (ODS). This multicenter study aimed to compare characteristics of MSFB, MSFBO, and ODS. Methods A multicenter international retrospective cohort study was conducted on adults with MSFBs and ODS who underwent sinus surgery. First in MSFBs, it was determined whether different dental conditions were more likely in FB versus non‐FB sides. Second, clinical features and dental pathologies were compared between MSFBO and ODS. For analyses, dental conditions were considered individually and as two groups: infectious pathologies and dental/oral procedures with indwelling metallic materials. Results After exclusions, there were 203 MSFBs and 163 ODS. Among MSFBs, 141 were MSFBOs. FB sides were associated with sinus protrusion of root canal treatment (RCT) materials ( p = 0.040) and dental implants ( p = 0.040). Compared to MSFBO, ODS patients were younger, more likely to have MS purulence (OR = 40.9, p < 0.010), more likely associated with apical periodontitis (OR = 2.59, p = 0.010) and oroantral fistulas (OR = 6.94, p = 0.020), and less likely associated with extruded RCT materials (OR = 0.01, p = 0.010) and protruded midface screws (OR < 0.01, p = 0.010). Comparing purulent MSFBO and ODS, ODS was more associated with infectious dental pathologies ( p < 0.009). Conclusion Compared to MSFBs, MSFBOs were associated with RCT extrusion and implant protrusion. Compared to MSFBOs, ODS was more likely purulent and associated with infectious dental pathologies. While ODS is often distinct from MSFBO, the two conditions can coexist, and surgeons must determine whether patients have infectious dental pathology requiring treatment with both conditions. Level of Evidence 4.
Picture living with diabetes: A photovoice study of young adults' efforts in making diabetes care fit into their lives
Gastel, Anka Van, Graner‐Baars, Matthijs, Koning, Eelco J.P. de , Tran, V., Dinneen, Sean R. , Mesman, Jessica, Swaak, Joris, Aanstoot, Henk‐Jan, Stiggelbout, Anne, Kunneman, Marleen, Mesman, Jessica , Van Gastel, Anka , De Koning, Eelco J P , Dinneen, Sean F , Kunneman, Marleen , Graner, Matthijs, Montori, Víctor M. , Tran, Viet-Thi , Aanstoot, Henk‐Jan , Kunneman, Marleen

Mayo Clinic

Diabetic Medicine | February 6, 2026 | Volume: 43 | Issue: 5 | Pages: No page available

10.1111/dme.70246 | PMID 41645388 Get It

Abstract Aim This study aimed to identify what young adults with type 1 diabetes (T1D) do to make diabetes care fit in their lives and the impact of diabetes and diabetes care on living. Methods Dutch young adults with T1D (18–30 years old) submitted photographed real‐life situations of efforts to make care fit and of the impact of care on their lives. Participants organised their photos in themes, which guided the focus group discussions. We added a reflective questionnaire, semi‐structured interview and iterative validation to identify participant‐defined themes and summarise the data. Results Participants ( N = 18) submitted 240 photographs in total, showing a broad range of situations and emotions. Participants identified 16 themes, grouped into four overarching categories describing their experiences with diabetes: (1) My diabetes: glucose levels, workload, 24/7 present; (2) My life: flow of (daily) life, special and irregular circumstances, life changes, body and health; (3) Support: devices and technology, social network, clinical (diabetes) care; (4) Mental aspects: emotional processes, perspective, being a patient. In the overlap of My diabetes and My life, they identified eating and counting carbohydrates, activity and exercise, recreational substances. Conclusion Young adults with T1D face the complex challenge of fitting their care into their ever‐changing lives. While support systems, such as devices, healthcare professionals and social networks can help, they can also create burdens. Participants emphasised the importance of mental health in their lives with T1D. This study highlights the need for diabetes care that acknowledges the emotional, social and practical realities of young adults' lives.
Integrative Multi-Omics Analysis Identifies a Functional Enhancer Driving Tumorigenesis in Head and Neck Squamous Cell Carcinoma
Liu, Xiaorong, Pu, Jane Jingya, Lu, Xiaoling , Wang, Evelyn Yilin, Jiang, Qianhui , Yu, Dan , Yan, Bin, Zhong, Qi, Yang, Ping, Su, Yu-Xiong, Yu, Dan , Xu, Pengfei , Lee, Victor , Song, Jinlin , Tran, Nhan L. , Guan, Xinyuan , Wang, Yi-Xiang

Mayo Clinic

No container title available | February 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.03.703438 Get It

Abstract Enhancer is a critical epigenetic feature in head and neck squamous cell carcinoma (HNSCC), yet the functional roles of individual enhancers remain poorly understood. Here, we conducted an integrative multi-omics analysis based on publicly available ATAC-seq, H3K27ac ChIP-seq, transcriptomic profiling, and genetic association datasets to systematically map HNSCC-associated enhancers and their target genes. Integrating ATAC-seq and H3K27ac ChIP-seq, we identified 20,362 enhancers and 18,040 enhancer-associated genes, highlighting widespread regulatory complexity. Functional characterization of the TERT -associated enhancer GH05J001312 (GRCh38/hg38: chr5:1312099-1317743) revealed strong transcriptional activity in HNSCC. CRISPR-mediated deletion of a core sequence significantly reduced TERT expression, impaired cellular proliferation in vitro , and suppressed tumor growth in vivo , confirming its role as a key cis-regulatory element. RNA-seq analysis of enhancer-edited cells uncovered 742 differentially expressed genes enriched in cancer-related pathways, including MAPK and IL-17 signaling, indicating a broad transcriptional impact. Collectively, our findings establish GH05J001312 as a functional enhancer driving oncogenic programs in HNSCC and suggest enhancer-targeted strategies as a potential therapeutic avenue.